Antibiotic Prophylaxis With Routine Ureteral Stent Removal

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-31

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will be a single-institutional randomized, single-blinded prospectively controlled clinical trial of a single dose of Ciprofloxicin 500mg antibiotic tablet as prophylaxis at the time of office flexible cystoscopy with ureteral stent removal. The control group will be no prophylaxis oral antibiotics.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Struvite Stones Antibiotic Study

NCT02375295

Kidney Stones

UNKNOWN PHASE4

Antibiotic Prophylaxis Before Shock Wave Lithotripsy

NCT03692715

Ureteral Stones Ureteral Calculi Nephrolithiasis

COMPLETED PHASE4

Efficacy of Antimicrobial Prophylaxis for Shock Wave Lithotripsy (SWL) on Reducing Urinary Tract Infection (UTI)

NCT01873690

Urolithiasis

TERMINATED PHASE3

Antibiotic Selection Using Next Generation Sequencing vs Urine Culture

NCT04404855

Kidney Stone Renal Stone Infection, Bacterial

COMPLETED NA

Antibiotic Prophylaxis for Ureteroscopy With a Negative Pressure Suction Sheath

NCT07246967

Urolithiasis Antibiotics

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be a single-institutional randomized, single-blinded prospectively controlled clinical trial of a single dose of Ciprofloxicin 500mg antibiotic tablet as prophylaxis at the time of office flexible cystoscopy with ureteral stent removal. The control group will be no prophylaxis oral antibiotics. The study will be conducted at UCSD Urology outpatient clinic and Genesis Healthcare Partners Urology outpatient clinic. UCSD will be the coordinating institution.

Treatment Assignment:

Patients will be assigned to control or intervention arm based on a predetermined allocation sequence that will be generated by a computerized random number generator. Study staff not participating in patient recruitment or procedure will manage the allocation sequence. Physicians involved in urologic patient care will be blinded from the participants' allocation. Only study staff at the coordinating institution (UCSD) will have access to the full allocation sequence. i.e. no clinical staff involved in recruiting and consenting patients for the study at UCSD or other participating institutions will have knowledge of the allocation sequence at their institution prior to enrollment of each patient. To further aid allocation concealment, the block size will be varied.

Standard of care procedures:

Patients will be identified at the time of clinic visit for cystoscopic stent removal. All patients will be counseled on the American Urological Association's clinical guidelines for prophylactic antibiotic use, and the varied standardization of practice patterns. We will not deviate from routine care standards. Patients undergoing routine ureteral stent removal within two weeks following stone treatment procedure (ie. Percutaneous Nephrolithotomy, Ureteroscopy, Retrograde Intrarenal Surgery, or Extracorporal Shockwave Lithotripsy). Patients that agree to participate and provide consent will be enrolled into the study, receiving a randomized allocation, and specific data points will be collected prospectively. Patients will be consented prior to determination of prophylaxis for collection of demographic, disease, perioperative, and postoperative data. If the patient does not consent to the study the use of antibiotics will be based on the routine clinical practice of the treating urologist.

Investigational portion of treatment:

Patients randomized to the intervention arm will be provided a single oral dose of Ciprofloxacin 500mg at the time of stent removal. Ciprofloxacin is currently indicated for the treatment of acute uncomplicated urinary tract infections. Patients with fluoroquinalone allergy will receive Bactrim (trimethoprim/sulfamethoxazole 160/800mg) single dose instead of Ciprofloxacin. Those patients that do develop infectious complications after stent removal will be treated empirically based on the preference of the treating physician followed by culture specific antibiotics. Centeral prophylaxis randomization will take place at UCSD, as the lead site, using staff members not involved in patient management. Randomization will occur in block randomization in block sizes of 10.

Standard of care procedures Patients will have cystoscopy and stent removal performed in standard fashion, without deviation from standard of care. The time frame of stent removal after initial stone procedure is consistent with current standard of care. If the treating physician's preference is to maintain the patient's indwelling stent for longer than two weeks, then the patient would not be considered for this study. No patient's management course will be altered for inclusion into this study.

All female patients are screened with a urinary pregnancy test during the preoperative screening visit, which occurs before the kidney stone surgery. Any pregnant female patients will be excluded from participation in this study. Post-operative instructions include refraining from sexual activity. Cystoscopic stent removal is performed within 14 days of surgery.

Demographic fields that will be obtained preoperatively include age, race, gender, body mass index (BMI), and comorbidities including history of diabetes mellitus, immunosuppression, prior urinary tract infection(s), neurogenic bladder, incomplete bladder emptying. Pre-operative clinical data points will include kidney stone size (largest diameter as measured on coronal imaging for either kidney-ureter-bladder plain x-ray or computerized tomography) and pre-operative urine culture results.

Post-procedure fields will include post-void residual urine volume per bladder scan (to assess emptying capability), culture of urine collected during stent removal (only to be treated with antibiotics if patient becomes symptomatic - per standard of care), stone culture results, stone analysis, and stone-free status. Phone call interview will occur between 7-14 days post-operatively to determine if any post-operative infectious events have occurred. Any infectious symptoms (see below) will prompt mid-stream clean catch specimen for urinalysis and urine culture. During this period, patients will be closely observed for infectious complication--ie. symptomatic urinary tract infection, defined as presence of bacteruria (\>5k colony forming units) with any of the following: fever \>38 C, malodorous urine, dysuria, urinary frequency, urinary urgency, lower abdominal discomfort, back pain, gross hematuria. . Patients will be evaluated at 8 weeks for re-assessment in the clinic with a renal bladder ultrasound performed at 6 weeks, which is the routine post-operative care.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urolithiasis UTI

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Antibiotic

Patients randomized to the intervention arm will be provided a single oral dose of prophylactic oral antibiotic at the time of cystoscopic stent removal

Group Type ACTIVE_COMPARATOR

Ciprofloxacin

Intervention Type DRUG

first line prophylactic oral antibiotic

trimethoprim/sulfamethoxazole

Intervention Type DRUG

second line prophylactic oral antibiotic

No Antibiotic

Patients randomized to the non-intervention arm will not undergo prophylaxis at the time of cystoscopic stent removal

Group Type ACTIVE_COMPARATOR

No Intervention

Intervention Type DRUG

No intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ciprofloxacin

first line prophylactic oral antibiotic

Intervention Type DRUG

trimethoprim/sulfamethoxazole

second line prophylactic oral antibiotic

Intervention Type DRUG

No Intervention

No intervention

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bactrim Septra

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with indwelling ureteral stents placed within the 2 weeks prior to the procedure visit for removal

Exclusion Criteria

* Patients with indwelling urethral catheter
* Patients with indwelling suprapubic catheter
* Patients with indwelling nephrostomy tube
* Patients who perform clean intermittent catheterization
* Pregnancy

Eligible Sex

ALL

Accepts Healthy Volunteers

No